Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.041
0.000
Volume:480.25K
Turnover:19.77K
Market Cap:43.11M
PE:-4.51
High:0.042
Open:0.040
Low:0.040
Close:0.041
52wk High:0.063
52wk Low:0.037
Shares:1.05B
Float Shares:863.70M
Volume Ratio:0.55
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.009
EPS(LYR):-0.009
ROE:-49.72%
ROA:-26.95%
PB:3.79
PE(LYR):-4.51

Loading ...

Company Profile

Company Name:
PRESCIENT THERAPEUTICS LTD
Exchange:
ASX
Establishment Date:
1986
Employees:
3
Office Location:
Suite 2,Level 11,385 Bourke Street,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9077 9233
Introduction:
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.